Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent buys Chinese rights to Incyte drugs for $40M upfront

fiercebiotechDecember 18, 2018

Tag: Innovent , Oncology , Incyte , hematology drugs , pharmaceutical companies

PharmaSources Customer Service